Log In
Print
BCIQ
Print
Print this Print this
 

Fosrenol, lanthanum carbonate

Also known as: formerly Foznol

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionLanthanum carbonate that binds phosphate in the diet to form insoluble lanthanum phosphate
Molecular Target Phosphate
Mechanism of ActionPhosphate binder
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHyperphosphatemia
Indication DetailsControl hyperphosphatemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphate level >= 1.78 mmol/L (5.5 mg/dL); Evaluate side effects of hyperphosphatemia treatment; Treat hyperphosphatemia; Treat hyperphosphatemia in patients with chronic kidney disease (CKD); Treat hyperphosphatemia in patients with end-stage renal disease (ESRD); Treat hyperphosphatemia in patients with stage III and IV chronic kidney disease (CKD)
Regulatory Designation

Partner

Bayer AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today